Roger Jeffs Sells 25,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Posted by George Bondi on May 26th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) CEO Roger Jeffs sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $61.13, for a total value of $1,528,250.00. Following the completion of the transaction, the chief executive officer owned 1,098,095 shares of the company’s stock, valued at $67,126,547.35. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00.
On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $58.65, for a total transaction of $1,466,250.00.
On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $57.04, for a total transaction of $1,426,000.00.
On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $56.29, for a total transaction of $1,407,250.00.
On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total transaction of $1,037,500.00.
On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $42.09, for a total transaction of $1,052,250.00.
On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total transaction of $1,002,500.00.
On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total value of $1,003,500.00.
On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.

Liquidia Stock Down 1.4%

Shares of LQDA stock traded down $0.88 on Tuesday, hitting $60.10. 1,283,528 shares of the stock were exchanged, compared to its average volume of 1,696,211. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $5.34 billion, a P/E ratio of 429.32 and a beta of 0.41. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $62.30. The business has a 50-day moving average of $42.53 and a 200 day moving average of $37.56.

Liquidia (NASDAQ:LQDA – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. Equities analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. Finally, Needham & Company LLC raised their price objective on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and an average target price of $49.33.

View Our Latest Analysis on LQDA

Institutional Investors Weigh In On Liquidia

Several large investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC grew its stake in shares of Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after buying an additional 90,400 shares in the last quarter. Vanguard Group Inc. lifted its stake in Liquidia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after acquiring an additional 52,671 shares during the last quarter. Opaleye Management Inc. lifted its stake in Liquidia by 9.5% in the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after acquiring an additional 215,000 shares during the last quarter. Bank of America Corp DE grew its position in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares during the period. Finally, Caprock Group LLC grew its position in shares of Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after acquiring an additional 151,832 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).